Inhibitory FcγRIIb and CD20 internalization

Ian Dransfield

doi:10.1182/blood-2013-12-539874

Inhibitory FcγRIIb and CD20 internalization

Ian Dransfield

Research output: Contribution to journal › Comment/debate

Abstract

In this issue of Blood, Vaughan et al demonstrate that certain antibodies that are used therapeutically in lymphoma treatment (e.g., rituximab) undergo Fcg receptor IIb (FcgRIIb)–mediated internalization from the B-cell surface in a manner that is independent of activation of FcgRIIb with important implications for the design of antibody-based therapeutics (see figure).

Original language	English
Pages (from-to)	606-7
Number of pages	2
Journal	Blood
Volume	123
Issue number	5
DOIs	https://doi.org/10.1182/blood-2013-12-539874
Publication status	Published - 30 Jan 2014

Keywords / Materials (for Non-textual outputs)

Antibodies, Monoclonal
Humans
Receptors, IgG

Access to Document

10.1182/blood-2013-12-539874

Cite this

@article{365c520d094e4d3ab39bf5f598efc9be,

title = "Inhibitory FcγRIIb and CD20 internalization",

abstract = "In this issue of Blood, Vaughan et al demonstrate that certain antibodies that are used therapeutically in lymphoma treatment (e.g., rituximab) undergo Fcg receptor IIb (FcgRIIb)–mediated internalization from the B-cell surface in a manner that is independent of activation of FcgRIIb with important implications for the design of antibody-based therapeutics (see figure).",

keywords = "Antibodies, Monoclonal, Humans, Receptors, IgG",

author = "Ian Dransfield",

year = "2014",

month = jan,

day = "30",

doi = "10.1182/blood-2013-12-539874",

language = "English",

volume = "123",

pages = "606--7",

journal = "Blood",

issn = "0006-4971",

publisher = "Elsevier",

number = "5",

}

TY - JOUR

T1 - Inhibitory FcγRIIb and CD20 internalization

AU - Dransfield, Ian

PY - 2014/1/30

Y1 - 2014/1/30

N2 - In this issue of Blood, Vaughan et al demonstrate that certain antibodies that are used therapeutically in lymphoma treatment (e.g., rituximab) undergo Fcg receptor IIb (FcgRIIb)–mediated internalization from the B-cell surface in a manner that is independent of activation of FcgRIIb with important implications for the design of antibody-based therapeutics (see figure).

AB - In this issue of Blood, Vaughan et al demonstrate that certain antibodies that are used therapeutically in lymphoma treatment (e.g., rituximab) undergo Fcg receptor IIb (FcgRIIb)–mediated internalization from the B-cell surface in a manner that is independent of activation of FcgRIIb with important implications for the design of antibody-based therapeutics (see figure).

KW - Antibodies, Monoclonal

KW - Humans

KW - Receptors, IgG

U2 - 10.1182/blood-2013-12-539874

DO - 10.1182/blood-2013-12-539874

M3 - Comment/debate

C2 - 24482497

SN - 0006-4971

VL - 123

SP - 606

EP - 607

JO - Blood

JF - Blood

IS - 5

ER -

Inhibitory FcγRIIb and CD20 internalization

Abstract

Keywords / Materials (for Non-textual outputs)

Access to Document

Fingerprint

Cite this